Swedish Orphan Fair Value
BI
The fair market value of BIOVF stock is 22.4 USD. Relative to the market price of 31.38 USD Swedish Orphan is overvalued by 28.6%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Swedish Orphan Valuation
Current BIOVF share ticker price is 31.38 USD.
The fair value level of 22.4 USD can be considered as an effective entry point for long-term investors to start investing in BIOVF stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 29% higher its fair value
Current price is 54% higher its minimum value
Current price is 4% lower its maximum value
Market price:
BIOVF stock is overvalued
It means the current price may concern as a Risky Entry Point
Swedish Orphan Biovitrum AB (publ) Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
35.42
2
Median P/E over 5 years
24.2
3
Minimum P/E over 5 years
15.46
4
Earning per share (last 12 months)
10.08 SEK
Maximum value
1
x
4
=
32.79 USD
Fair value
2
x
4
=
22.4 USD
Minimum value
3
x
4
=
14.32 USD
Swedish Orphan Biovitrum AB (publ) price metrics
15.82
Annual return (geometric mean)
36.48
Risk (standard deviation) of returns
β
0.54
Beta (volatility compared to market)